Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_2
1
33%
Ph phase_1
1
33%
Ph phase_3
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(2)
Other(1)

Detailed Status

Completed2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 31 (33.3%)

Trials by Status

unknown133%
completed267%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_1

Radioligand fOr locAl raDiorecurrent proStaTe cancER

NCT05230251
unknownphase_3

Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma

NCT02773485
completedphase_2

A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma

NCT02805179

Clinical Trials (3)

Showing 3 of 3 trials
NCT05230251Phase 1

Radioligand fOr locAl raDiorecurrent proStaTe cancER

Completed
NCT02773485Phase 3

Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma

Unknown
NCT02805179Phase 2

A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma

Completed

All 3 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
3